Biocompatibility Testing is the evaluation of how a medical device and its materials interact with the body to confirm they do not cause harmful biological responses. Guided by the ISO 10993 series, it assesses risks such as cytotoxicity, sensitization, and irritation based on the nature and duration of patient contact.
What is Biocompatibility Testing?
Biocompatibility Testing is the structured assessment of the biological safety of device materials that contact the patient, either directly or indirectly. It sits inside the broader biological evaluation required during design and verification, and it feeds the device’s risk management file.
The core question is simple: does anything the device touches, or anything that leaches from it, create an unacceptable biological response? The answer comes from a mix of material characterization, chemical analysis, and, where needed, laboratory testing of specific biological endpoints.
Why Biocompatibility Testing matters in medical device development
Materials that seem inert can still cause problems. Residual processing aids, adhesives, colorants, and sterilization byproducts can leach out and trigger irritation, allergic response, or worse over the life of the device.
Regulators treat biological safety as a gating issue. A weak biological evaluation is a common reason FDA 510(k) submissions and EU MDR 2017/745 technical files get rejected or delayed. Testing also takes time. Some animal-based assays run for weeks, so a missed endpoint discovered late can push a launch by a full quarter.
There is a cost dimension too. Running the wrong tests, or repeating them after a material change, is expensive. Planning the biological evaluation early, alongside design controls, keeps the program predictable and reduces audit exposure.
How Biocompatibility Testing works
Testing follows a risk-based path defined by ISO 10993-1, which acts as the framework standard for the whole series. You categorize the device first, then select endpoints, then decide whether existing data answers the question or new testing is required.
The typical sequence looks like this:
- Categorize the device by contact. Classify it as surface, external communicating, or implant, and by contact duration: limited (up to 24 hours), prolonged (24 hours to 30 days), or long-term (over 30 days).
- Characterize the materials. Document every patient-contacting material, its supplier, and its processing history. Chemical characterization under ISO 10993-18 identifies extractables and leachables.
- Select biological endpoints. Use the ISO 10993-1 matrix to map the contact category to the required endpoints. Common ones include cytotoxicity (ISO 10993-5), sensitization and irritation (ISO 10993-10 and -23), and systemic toxicity (ISO 10993-11).
- Run a toxicological risk assessment. Compare identified chemicals against safe exposure thresholds. This step, driven by ISO 10993-17, can sometimes replace animal testing when the chemistry is well understood.
- Test what remains. Conduct laboratory assays for endpoints that data alone cannot close.
- Document the conclusion. Compile a biological evaluation report that links results back to the risk management file under ISO 14971.
FDA reviews this work against its 2023 guidance on the use of ISO 10993-1, and notified bodies expect the same rigor for EU MDR. The trend across both is clear: lead with chemistry and risk assessment, and use biological assays to confirm, not to substitute for thinking.
Common challenges and best practices
The most frequent mistake is treating biocompatibility as a checkbox at the end of the design. By then, the materials are locked, and any failure means a redesign. Start the biological evaluation plan during concept and feasibility instead.
A second pitfall is poor material documentation. If you cannot trace a polymer grade, its additives, and its sterilization method, you cannot defend a chemical characterization. Teams that keep tight material specifications and supplier records spend far less time chasing data during review.
Sterilization changes the picture more than people expect. Ethylene oxide residuals, radiation effects on polymers, and packaging interactions all influence biological safety, so test the device in its final, sterilized, packaged form rather than raw material coupons.
Good programs also use existing data well. Equivalence arguments, prior testing on the same material in the same contact category, and published toxicological data can all reduce new testing. The catch is that the justification must be documented and specific to your device, not a generic claim.
How SJML helps with Biocompatibility Testing
SJML supports biocompatibility within its Compliance-as-a-Service offering, building the biological evaluation into the wider regulatory and risk management workflow. The team helps plan the evaluation strategy, organize material characterization and supplier data, and align biological safety files with ISO 14971 risk management and ISO 13485 quality requirements. This connects directly to SJML’s design and engineering work, so material choices, sterilization, and packaging are considered together rather than in isolation. Support extends to technical files for FDA 510(k) and EU MDR/IVDR submissions, where biological safety is a review focus.
Frequently asked questions
The ISO 10993 series governs it, with ISO 10993-1 as the framework that drives the biological evaluation. Individual parts cover specific endpoints, such as ISO 10993-5 for cytotoxicity and ISO 10993-18 for chemical characterization. FDA and EU MDR both recognize the series, though FDA adds its own guidance on how to apply ISO 10993-1.
No. The current approach favors chemical characterization and toxicological risk assessment first. When extractables and leachables are well understood and fall below safe thresholds, that data can satisfy several endpoints without new animal studies. Animal testing is reserved for questions that chemistry and existing data cannot answer.
Plan it during concept and feasibility, as soon as patient-contacting materials are proposed. Early planning lets you pick materials that are easier to defend and avoids late redesigns. Actual laboratory testing usually happens during design verification, once the device, sterilization method, and packaging are finalized.
Often, yes. A new supplier, grade, colorant, or sterilization method can change the chemical profile and the biological response. Assess each change through your risk management process. Some changes need full retesting, while others can be justified with a documented equivalence rationale tied to the original evaluation.
Related terms
- Biological Evaluation
- ISO 10993
- Risk Management (ISO 14971)
- Design Verification
- Sterilization Validation
